Geographic Atrophy

Iveric Bio announces positive topline data for avacincaptad for GA

Iveric bio, Inc announced positive topline results from GATHER2, a phase 3 clinical trial of avacincaptad pegol (Zimura) for the treatment of geographic atrophy (GA). Avacincaptad is a novel investigational complement C5 inhibitor. GATHER2 met its prespecified primary endpoint of mean rate of growth (slope) in GA area at 12...